Gubra WKN: A3D9NV ISIN: DK0062266474 Kürzel: PI3 Forum: Aktien User: Bärliner

📉📉📉🥲

Gubra launches Gubra Ventures and appoints Zoë Johnson to lead new venture creation unit Gubra today announced the launch of Gubra Ventures, a new business unit focused on creating independent biotechnology companies from high-quality scientific innovation. Zoë Johnson has been appointed Head of Gubra Ventures and will lead the identification, development, and early growth of new ventures in close collaboration with Gubra’s scientific teams and leadership. Gubra Ventures is designed to complement Gubra’s core research activities by incubating selected high-potential programs within dedicated venture structures. Each venture will be established with its own governance and leadership, enabling focused development while creating multiple pathways for long-term value creation. This approach allows promising science to be advanced efficiently, with greater flexibility and speed, without diluting Gubra’s core business. “Gubra Ventures is a natural next step in the evolution of our business model,” said Markus Rohrwild, CEO of Gubra. “Our scientific platforms have reached a level of scale and maturity where we can explore new opportunities with greater agility. This structure allows us to advance promising science in a focused way while expanding our pipeline and long-term value creation potential.” As Head of Gubra Ventures, Dr. Johnson will work closely with Gubra’s teams to ensure strategic alignment and to fully leverage the company’s scientific expertise, infrastructure, and capabilities. “Gubra Ventures is built to turn strong science into focused, capital-efficient companies,” said Zoë Johnson. “By incubating programs within venture structures that are purpose-built for them, we can accelerate development while maintaining flexibility for future partnering or growth. I am excited to join Gubra at a pivotal moment and to help shape the next generation of companies emerging from its science.” Dr. Johnson brings more than 20 years of experience across early-stage innovation, translational biology, and venture creation in both pharma and biotech. She has held senior R&D leadership roles spanning discovery through clinical development, with expertise across immunology, inflammation, oncology, and cardiometabolic disease. Most recently, her work has focused on early company building at the intersection of science, strategy, and execution. The launch of Gubra Ventures underscores Gubra’s commitment to maximizing the impact of its scientific platform while expanding development and partnership opportunities

CAMBRIDGE, Mass. January 8, 2026 – Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S (“Gubra”), a company specializing in peptide-based drug discovery and preclinical contract research services. “We are very pleased to nominate AMX0318 as a development candidate and were highly impressed by Gubra’s proprietary and innovative process, which identified a peptide that surpassed our research target profile for a long-acting GLP-1 receptor antagonist. AMX0318 has thus far shown robust preclinical and chemical properties, including a pharmacokinetic profile that may support long-acting administration,” said Camille L. Bedrosian, MD, Chief Medical Officer at Amylyx. “We are excited about the opportunity to develop additional therapeutic possibilities for people who may benefit from inhibiting GLP-1 receptor activity, including people with PBH and other rare diseases. The GLP-1 receptor is a well-characterized biological target and one of the key regulators of glucose-insulin homeostasis.” Dr. Bedrosian continued, “We have strong conviction that inhibiting GLP-1 receptor activity represents an important therapeutic approach given the statistically significant data that avexitide, our investigational, first-in-class GLP-1 receptor antagonist, has generated to date. We continue to expect completion of recruitment in our pivotal Phase 3 LUCIDITY trial of avexitide in Q1 2026, with topline data expected in Q3 2026.” AMX0318 has completed extensive preclinical evaluation, including stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and in vivo tolerability studies. Amylyx expects the program to advance into investigational new drug (IND)-enabling studies later this year, with an IND targeted for 2027, pending successful completion of IND-enabling studies. “We are pleased to see AMX0318 advance as a development candidate, a milestone that reflects both the strong collaboration between the Gubra and Amylyx teams and the capabilities of Gubra’s proprietary peptide drug discovery platform,” said Louise S. Dalbøge, Chief Science Officer at Gubra. “Our AI-driven streaMLine platform enables multi-parameter optimization of peptide candidates, and we are excited to see this applied successfully to AMX0318 in close collaboration with Amylyx.”

Gubra appoints Dr. Thomas Langenickel as Chief Medical and Development Officer Gubra today announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO). Dr. Langenickel brings more than two decades of experience in big pharma and biotech, spanning drug discovery, translational medicine, and clinical development. In his new role, he will join Gubra’s Leadership Team and guide the company’s preclinical and clinical development strategy as its pipeline advances toward key milestones. “We are delighted to welcome Thomas to Gubra. His deep expertise in translational medicine and clinical development will be instrumental as we strengthen our internal pipeline and broaden our therapeutic footprint. Thomas’ appointment reflects our ambition to become a leading peptide-centric, disease-agnostic techbio company,” said Markus Rohrwild, CEO of Gubra. As Gubra progresses its internal programs – including the UCN2 program aimed at delivering high-quality weight loss – the company will further expand its clinical capabilities to ensure a seamless transition from discovery to clinical proof-of-concept. “I’m thrilled to join Gubra at such an exciting inflection point. The company’s ambition and scientific depth provide an exceptional foundation for advancing a pipeline of first- and best-in-class therapeutics. I very much look forward to working with the talented team to help realize this potential,” said Dr. Langenickel. Dr. Langenickel most recently served as CMO at Ethris, where he led the development of early clinical assets in respiratory and infectious diseases. His prior experience includes senior roles at Novartis as Executive Director of Translational Medicine and Profiling, and at Bristol Myers Squibb as Medical Director. He earned his M.D. from Humboldt University of Berlin and completed a postdoctoral fellowship in vascular biology at the National Heart, Lung, and Blood Institute, NIH (USA). Gubra also extends its gratitude to Dr. Mads Axelsen, who retired in December after serving as CMO. His leadership and contributions have been instrumental in shaping Gubra’s development organization and supporting the company’s growth.

https://www.finanznachrichten.de/nachrichten-2025-11/66909911-record-earnings-for-gubra-revised-outlook-for-the-cro-business-200.htm ... also zahlen gab es schon mal.

Kommen bald Ergebnisse? Steigt ja die letzten Tage.

Gubra und Novo sind halt dänischen bzw europäische Unternehmen. Eli Lilly ist der amerikanische Gegenspieler/ Konkurrent von Novo

Ich habe beobachtet, wenn Eli Lilly steigt, sinkt Gubra. Was auch immer das bedeuten kann. Ich denke es ist Zufall.

Man erkennt schon ein leichten Zusammenhang. Wenn Novo sinkt, dann sinkt Gubra auch. War in der Vergangenheit auch so. Bin deshalb ja auf Gubra aufmerksam geworden.

Was soll der Kurs von Gubra mit Novo zu tun haben? Gubra glänzt nicht gerade mit Neuigkeiten über aktuelle Errungenschaften. Wo soll der Umsatz und der Gewinn herkommen? Im Moment denke ich nicht daran hier wieder zu investieren 🤷🏻‍♂️📉

Wegen Novo 📉🤷🏼‍♂️

Was'n hier los?

Zum nachschauen: Ausgabe: 43/2025 Verkauf Porsche AG PAG911 175 13.10.25 41,94 € -32,4 % Verkauf Gubra A3D9NV 125 13.10.25 56,40 € +25,3 % Zusammen mit PAG, um dieses Gegenzurechnen. Und mit der Kohle haben die Rio Tinto gekauft.

Stimmt doch garnicht!

Der Aktionär hat seine Anteile im Depot diese Woche verkauft. Wahrscheinlich die Schnauze voll.😅

Sieht gut aus im Moment 👍